| Objective: To investigate the expression of Nrf2 and NQO1 in gastric cancer tissue and adjacent non-tumor tissues and evaluate their clinical significance; To study the role of Nrf2 / NQO1 signaling pathways in the progress of gastric cancer; To explore the effect of the expression of Nrf2 and NQO1 on chemosensitivity to 5-FU combination chemotherapy in gastric cancer.Methods: Collected gastric carcinoma and adjacent normal tissues. Immunohistochemistry staining was used to detect the expression of Nrf2 and NQO1 in gastric cancer tissue and adjacent non-tumor tissues in 92 cases. The Chi-square Test was performed to evaluate the association between the expression of Nrf2 or NQO1 and clinicopathological factors in gastric cancer.Results: The positive rates of Nrf2 and NQO1 protein expression in gastric cancers were 59.78% and 55.43%, respectively. Both Nrf2 and NQO1 positivity were closely associated with tumor size, lymph node metastasis, TNM stage, tumor depth and the degree of histological differentiation(P<0.05 for all). Both Nrf2 and NQO1 are significantly correlated with resistance to 5-fluorouracil combination chemotherapy in gastric cancer(P= 0.001 and 0.009, respectively).Conclusion: There was a positive correlation between expression of Nrf2 and NQO1. Both of them correlated with tumor size, lymph node metastasis, TNM stage, tumor depth, the degree of histological differentiation and resistance to 5-fluorouracil combination chemotherapy in gastric cancer. These findings suggest that Nrf2 and NQO1 expression reflect aggressive behavior of gastric cancer. Nrf2 and NQO1 might be useful as a poor prognostic biomarker of gastric cancer. Nrf2 and NQO1 high expression might reduce the effect of 5-fluorouracil combination chemotherapy in gastric cancer. We can predict the efficacy of 5FU-based adjuvant chemotherapy in gastric cancer by evaluation of Nrf2 or NQO1 expression. Of course, Nrf2 and NQO1 may be potential molecular targets for therapy. |
PDF Full Text Request